Peer review reports
From: Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
Original Submission |
23 Jun 2023 |
Submitted |
Original manuscript
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
25 Aug 2023 |
Reviewed |
Reviewer Report
|
16 Oct 2023 |
Reviewed |
Reviewer Report
|
30 Oct 2023 |
Author responded |
Author comments - Xiaojia Wang
|
Resubmission - Version 4 |
30 Oct 2023 |
Submitted |
Manuscript version 4
|
Publishing |
14 Dec 2023 |
Editorially accepted |
|
2 Jan 2024 |
Article published |
10.1186/s12885-023-11764-8
|
Learn about peer review